Nebenwirkungen · Armisarte (previously Pemetrexed Actavis)
Armisarte 25 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-223774 · Präparat HOS-217236
Summary of the safety profile The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash, infection/sepsis and neuropathy. Rarely seen events include Stevens-Johnson syndrome and toxic epidermal necrolysis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-11T17:32:00Z · SHA-256 ad2d3dc28d4f7b5a98dcdc66bd5a74f1341b3c40625750424381ab6be3538c8d · Passage ddd6d66aad51d6a0dfbf74620f58428dd0d3b45265c1c342ce5f9929b359863d · Zeichen 0–616 im Abschnitt